Chemistry, physiology, and therapeutic applications of calcitonin

MacIntyre, I.; Evans, Imogen M. A.; Hobitz, H; Joplin, G. F.; Stevenson, John C.

doi:10.1002/art.1780231011

Cited by 58 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Optical densitometry was performed to evaluate the surgical bone defects in each specimen. 4,8 The radiographic images were digitalized, and bone mineral density (BMD) was reported as aluminum thickness. 4 Three measurements were performed per selected region, and the mean values obtained were multiplied by 0.5 (Fig.…”

Section: Optical Densitometrymentioning

confidence: 99%

“…The most common condition is the loss of action of gonadal steroids on bone, as observed in menopause or in male and female hypogonadism not associated with menopause. 3,6,[8][9][10]14,15 Osteoporosis is a skeletal disorder characterized by compromised bone strength, which predisposes the individual to a greater risk of fracture. In the United States, 26% of women aged 65 and older and more than 50% of women aged 85 and olcer have osteoporosis.…”

Section: Low-level Laser Therapy and Calcitonin In Bone Repairmentioning

confidence: 99%

“…3,4,6,7 This hormone favors bone formation, inhibits osteoclastic activity, and prevents osteopenia. 4,6,7 In vitro and in vivo studies have shown that this hormone stimulates the growth of bone tissue, 3,8 demonstrated by a decrease in inflammatory cell infiltration, tissue flattening, reduced number of lymphoid follicles, and other histological effects. 8 Since 1994, the World Health Organization (WHO) has recommended bone densitometry as the criterion standard for the diagnosis of osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Low-Level Laser Therapy and Calcitonin on Bone Repair in Castrated Rats: A Densitometric Study

Nascimento

Cardoso

Ribeiro

et al. 2010

Photomedicine and Laser Surgery

View full text Add to dashboard Cite

Objective: To investigate the healing of bone defects in male rats treated with salmon calcitonin, low-level laser therapy (LLLT), or both. Background: Healing of bone defects still represents a challenge to health professionals in several areas. In this article, the effect of calcitonin in combination with LLLT on bone repair was studied. Densitometry was used as a valuable tool for the measurement of bone regeneration. Methods: Sixty male Wistar rats underwent bilateral castration surgery before the creation of a surgical bone defect. The animals were randomly divided into four groups: control, treated with calcitonin (Ca), treated with LLLT (La), and treated with calcitonin and LLLT (CaLa). Groups Ca and CaLa received 2 IU=kg of synthetic salmon calcitonin intramuscularly three times a week. Groups La and CaLa received laser therapy using a gallium-aluminum-arsenide laser (10 mW, 20 J=cm 2 , wavelength 830 nm). Control animals were submitted to sham irradiation. The animals were sacrificed 7, 14, and 21 days after surgery, and bone defects were analyzed using densitometry. Results: The CaLa group had a higher degree of bone regeneration 14 and 21 days after surgery. Conclusions: The La and CaLa had significantly higher bone mineral density than the control and Ca groups.

show abstract

Section: Optical Densitometrymentioning

confidence: 99%

Section: Low-level Laser Therapy and Calcitonin In Bone Repairmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Low-Level Laser Therapy and Calcitonin on Bone Repair in Castrated Rats: A Densitometric Study

Nascimento

Cardoso

Ribeiro

et al. 2010

Photomedicine and Laser Surgery

View full text Add to dashboard Cite

show abstract

“…The three peptides, which share substantial structural homology (36), produce similar biological effects in many tissues, including bone (29). It is generally acknowledged that CT plays an important role in skeletal homeostasis, being a key modulator of bone resorption through a direct effect on osteoclasts (22). The hormone, CT, inhibits bone resorption by inducing quiescence of cell motility and retraction of osteoclasts (24), and chronic administration of CT reduces the number of osteoclasts (5).…”

mentioning

confidence: 99%

Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity

Villa¹,

Fiume²,

Maestroni

et al. 2003

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

The calcitonin peptides [calcitonin (CT), calcitonin gene-related peptide (CGRP), amylin] share many biological actions, including activity on bone cells. In the present study, CT (10−11 to 10−9 M) stimulated [3H]thymidine incorporation in primary cultures of human osteoblasts (hOB), as already demonstrated for CGRP and amylin. RT-PCR analysis showed that the calcitonin receptor and the calcitonin receptor-like receptor are both expressed in hOB. In these cells, CT (10−10 M) and amylin (10−9 M), in contrast to CGRP (10−8 M), did not increase cAMP production. All three peptides stimulated protein kinase C (PKC) activity. To evaluate PKC involvement in hOB proliferation, cells were incubated with phorbol 12,13-dibutyrate, a stimulator of PKC activity; cell proliferation was increased in a dose-dependent manner (EC50 = 3.4 × 10−8 M). Staurosporine (10−9 M), a PKC inhibitor, blocked phorbol 12,13-dibutyrate-induced PKC activity and cell proliferation. Inhibition of PKC by staurosporine also counteracted the stimulatory effect of CT, CGRP, and amylin on hOB proliferation. From these data, it is deduced that the activation of PKC is important for hOB proliferation and that it is involved in the anabolic effect of CT peptides on bone.

show abstract

“…It appears unlikely that patients treated with human calcitonin would become resistant due to antibody formation. However, resistance to continued administration has been observed in the absence of antibodies (20). This is unexplained, as in the case of patients treated with salmon calcitonin.…”

Section: Treatment Of Patients With Salmon Calcitonin Resistancementioning

confidence: 99%

Salmon calcitonin therapy for paget's disease of bone the problem of acquired clinical resistance

Singer

Fredericks

Minkin

1980

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

During the initial months of long‐term treatment of Paget's disease of bone with salmon calcitonin, circulating alkaline phosphatase activity and urinary hydroxyproproline excretion usually decrease by about 50%. In 22 of 85 patients these parameters returned to pretreatment levels despite continuous therapy. Nineteen patients who were resistant to salmon calcitonin had salmon calcitonin antibodies in high titer. Human calcitonin has been effective in suppressing disease activity in these patients. The pathogenesis of calcitonin resistance in patients without antibodies is unknown.

show abstract

Chemistry, physiology, and therapeutic applications of calcitonin

Cited by 58 publications

References 41 publications

Effect of Low-Level Laser Therapy and Calcitonin on Bone Repair in Castrated Rats: A Densitometric Study

Effect of Low-Level Laser Therapy and Calcitonin on Bone Repair in Castrated Rats: A Densitometric Study

Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity

Salmon calcitonin therapy for paget's disease of bone the problem of acquired clinical resistance

Contact Info

Product

Resources

About